Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tessema, Mathewos ^a   Yingling, Christin M ^a   Grimes, Marcie J ^a   Thomas, Cynthia L ^a   Liu, Yushi ^a   Leng, Shuguang ^a   Joste, Nancy ^b   Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PAX5; HIGH MOBILITY GROUP B PROTEIN; HIGH MOBILITY GROUP PROTEIN; MIG 7 PROTEIN, HUMAN; MIG-7 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TNRC9 PROTEIN, HUMAN; TOX PROTEIN, HUMAN; TOX2 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EXON; GC RICH SEQUENCE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN MOTIF; SMOKING; TOX GENE; TOX2 GENE; TOX3 GENE; TOX4 GENE; TRANSCRIPTION REGULATION; TUMOR GENE; TUMOR MICROENVIRONMENT; BREAST TUMOR; DNA SEQUENCE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG; LUNG TUMOR; MALE; METABOLISM; MOLECULAR GENETICS;

BASE SEQUENCE; BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH MOBILITY GROUP PROTEINS; HMGB PROTEINS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; RECEPTORS, PROGESTERONE; SEQUENCE ANALYSIS, DNA;

EID: 84859312823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034850     Document Type: Article

References (43)

1. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, et al. (2006) Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A 103: 982-987.
2. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, et al. (2008) Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 98: 466-473.
3. Ching TT, Maunakea AK, Jun P, Hong C, Zardo G, et al. (2005) Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet 37: 645-651.
4. Shiraishi M, Chuu YH, Sekiya T, (1999) Isolation of DNA fragments associated with methylated CpG islands in human adenocarcinomas of the lung using a methylated DNA binding column and denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 96: 2913-2918.
5. Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y, (2002) HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene 21: 3659-3662.
6. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, et al. (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312.
7. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681-8686.
8. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP, (1999) Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res 59: 4535-4541.
9. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, et al. (2001) Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 61: 8540-8546.
10. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, et al. (2008) Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3: e2079.
11. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, et al. (2003) Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 63: 4620-4625.
12. Thomas JO, Travers AA, (2001) HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 26: 167-174.
13. Travers AA, (2003) Priming the nucleosome: a role for HMGB proteins? EMBO Rep 4: 131-136.
14. Yuan F, Gu L, Guo S, Wang C, Li GM, (2004) Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem 279: 20935-20940.
15. Bewley CA, Gronenborn AM, Clore GM, (1998) Minor groove-binding architectural proteins: structure, function, and DNA recognition. Annu Rev Biophys Biomol Struct 27: 105-131.
16. O'Flaherty E, Kaye J, (2003) TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics 4: 13.
17. Soullier S, Jay P, Poulat F, Vanacker JM, Berta P, et al. (1999) Diversification pattern of the HMG and SOX family members during evolution. J Mol Evol 48: 517-527.
18. Stros M, (2010) HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 1799: 101-113.
19. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
20. Wilkinson B, Chen JY, Han P, Rufner KM, Goularte OD, et al. (2002) TOX: an HMG box protein implicated in the regulation of thymocyte selection. Nat Immunol 3: 272-280.
21. Kajitani T, Mizutani T, Yamada K, Yazawa T, Sekiguchi T, et al. (2004) Cloning and characterization of granulosa cell high-mobility group (HMG)-box protein-1, a novel HMG-box transcriptional regulator strongly expressed in rat ovarian granulosa cells. Endocrinology 145: 2307-2318.
22. Dittmer S, Kovacs Z, Yuan SH, Siszler G, Kogl M, et al. (2011) TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex. J Cell Sci 124: 252-260.
23. Yuan SH, Qiu Z, Ghosh A, (2009) TOX3 regulates calcium-dependent transcription in neurons. Proc Natl Acad Sci U S A 106: 2909-2914.
24. du Puch CB, Barbier E, Kraut A, Coute Y, Fuchs J, et al. (2011) TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs. Arch Biochem Biophys 507: 296-303.
25. Chakravarty G, Moroz K, Makridakis NM, Lloyd SA, Galvez SE, et al. (2011) Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood) 236: 145-155.
26. Hess JL, (1998) Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 109: 251-261.
27. Jia X, Li X, Xu Y, Zhang S, Mou W, et al. (2011) SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3: 230-238.
28. Jia Y, Yang Y, Liu S, Herman JG, Lu F, et al. (2010) SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 5: 743-749.
29. Tallini G, Dal Cin P, (1999) HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 6: 237-246.
30. Treff NR, Pouchnik D, Dement GA, Britt RL, Reeves R, (2004) High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene 23: 777-785.
31. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, et al. (2008) Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68: 2764-2772.
32. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, et al. (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377.
33. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
34. Tessema M, Willink R, Do K, Yu YY, Yu W, et al. (2008) Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 68: 1707-1714.
35. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, et al. (2010) Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29: 5159-5170.
36. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
37. Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, et al. (2012) SULF2 Methylation is Prognostic for Lung Cancer Survival and Increases Sensitivity to Topoisomerase-I inhibitors via Induction of ISG15. Oncogene 2011 Dec 12 doi: 101038/onc2011577 [Epub ahead of print].
38. Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, et al. (2001) The DNA sequence and comparative analysis of human chromosome 20. Nature 414: 865-871.
39. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
40. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, et al. (2006) Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66: 10621-10629.
41. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, et al. (2011) Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 71: 454-462.
42. Clark SJ, Melki J, (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21: 5380-5387.
43. Oyer JA, Chu A, Brar S, Turker MS, (2009) Aberrant epigenetic silencing is triggered by a transient reduction in gene expression. PLoS One 4: e4832.